Table 2 Ongoing randomised trials with selected immunotherapeuticsa in locoregionally advanced head and neck cancer (also including nasopharyngeal carcinoma) as of April 2017 (≥ 100 patients)
From: Immunotherapy in head and neck cancer: aiming at EXTREME precision
Trial, ClinicalTrials.gov identifier | Phase, setting | Estimated enrolment | Immunotherapeutic approach | Regimen (treatment arms A, B, C) | Primary completion date |
|---|---|---|---|---|---|
NCT02421640b | IIR, adjuvant | 116 | Adoptive T-cell transfer | A: Autologous TILse, f B: No adjuvant therapy | 3/2017 |
NCT02707588 (PembroRad) | IIR, definitive | 114 | Anti-PD-1 | A: Pembrolizumabe + RT B: Cetuximab + RT | 8/2017 |
NCT02841748 (PATHWay) | IIR, adjuvant | 100 | Anti-PD-1 | A: Pembrolizumabe B: Placebo | 8/2018 |
NCT02609386c (INSPIRE) | IIR, neo-adjuvant and adjuvant | 200 | Cytokines | A: IRX-2e + CIZO B: CIZO | 2/2019 |
NCT02764593 (RTOG 3504) | I/III, definitive and adjuvant | 120 | Anti-PD-1 | A: Nivolumabe + low-dose cisplatin + RT B: Nivolumabe + high-dose cisplatin + RT C: Nivolumabe + cetuximab + RT D: Nivolumabe + RT | 3/2019 |
NCT02999087 (REACH) | III, definitived | 688 | Anti-PD-L1 | A: Cisplatin + RT B, C: Cetuximab + avelumabe + RT D: Cetuximab + RT | 10/2019 |
NCT03040999 (KEYNOTE-412) | III, definitived | 780 | Anti-PD-1 | A: Pembrolizumabe + cisplatin + RT B: Placebo + cisplatin + RT | 3/2021 |
NCT02952586 (JAVELIN Head and Neck 100) | III, definitived | 640 | Anti-PD-L1 | A: Avelumabe + cisplatin + RT B: Placebo + cisplatin + RT | 4/2021 |